Can a Low-Fat meal ease side effects of NF1 tumor drug?

NCT ID NCT05101148

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 25 times

Summary

This study looks at whether taking the drug selumetinib with a low-fat meal reduces stomach side effects in teenagers with neurofibromatosis type 1 (NF1) who have tumors that cannot be removed by surgery. About 24 teens will take the drug under both fed and fasted conditions to compare drug levels and tolerability. The goal is to find a better way to take the medicine that keeps it working while causing fewer stomach issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Rochester, Minnesota, 55905, United States
Research Site

Akron, Ohio, 44308, United States
Research Site

Bydgoszcz, 85-094, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Warsaw, 02-091, Poland
Research Site

Moscow, 119620, Russia
Research Site

Moscow, 125412, Russia
Research Site

Barcelona, 08950, Spain
Research Site

Madrid, 28009, Spain

Conditions

Explore the condition pages connected to this study.

NEUROFIBROMATOSIS TYPE 1